These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12792668)

  • 41. Targeting Adenosine Receptors in Neurological Diseases.
    Atif M; Alsrhani A; Naz F; Imran M; Imran M; Ullah MI; Alameen AAM; Gondal TA; Raza Q
    Cell Reprogram; 2021 Apr; 23(2):57-72. PubMed ID: 33861641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats.
    Sebastião AM; Cunha RA; de Mendonça A; Ribeiro JA
    Br J Pharmacol; 2000 Dec; 131(8):1629-34. PubMed ID: 11139440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic challenge to glia activates an adenosine-mediated safety mechanism that promotes neuronal survival by delaying the onset of spreading depression waves.
    Canals S; Larrosa B; Pintor J; Mena MA; Herreras O
    J Cereb Blood Flow Metab; 2008 Nov; 28(11):1835-44. PubMed ID: 18612316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endogenous adenosine mediates the sustained inhibition of excitatory synaptic transmission during moderate hypoxia.
    Arlinghaus L; Lee KS
    Brain Res; 1996 Jun; 724(2):265-8. PubMed ID: 8828579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synaptic dysfunction and septin protein family members in neurodegenerative diseases.
    Marttinen M; Kurkinen KM; Soininen H; Haapasalo A; Hiltunen M
    Mol Neurodegener; 2015 Apr; 10():16. PubMed ID: 25888325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.
    Abbracchio MP; Cattabeni F
    Ann N Y Acad Sci; 1999; 890():79-92. PubMed ID: 10668415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Perspectives on the therapy of neuropsychiatric diseases with adenosinergic substances].
    Erfurth A; Schmauss M
    Fortschr Neurol Psychiatr; 1995 Mar; 63(3):93-8. PubMed ID: 7759049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P2Y Receptors in Synaptic Transmission and Plasticity: Therapeutic Potential in Cognitive Dysfunction.
    Guzman SJ; Gerevich Z
    Neural Plast; 2016; 2016():1207393. PubMed ID: 27069691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adenosine receptor control of cognition in normal and disease.
    Chen JF
    Int Rev Neurobiol; 2014; 119():257-307. PubMed ID: 25175970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Nucleotide receptors in learning and neuronal plasticity].
    Czajkowski R
    Postepy Biochem; 2014; 60(4):506-13. PubMed ID: 25807829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adenosine physiology and pharmacology: how about A2 receptors?
    Daval JL; Nicolas F; Doriat JF
    Pharmacol Ther; 1996; 71(3):325-35. PubMed ID: 8940747
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission.
    d'Alcantara P; Ledent C; Swillens S; Schiffmann SN
    Neuroscience; 2001; 107(3):455-64. PubMed ID: 11719000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adenosine, neurodegeneration and neuroprotection.
    Stone TW
    Neurol Res; 2005 Mar; 27(2):161-8. PubMed ID: 15829179
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [From energetics to neurotransmission: adenosine triphosphate and its receptors].
    Galindo F; Flores A
    Rev Neurol; 2006 Dec 1-15; 43(11):667-77. PubMed ID: 17133328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurodegeneration and neuroplasticity in the peripheral and central nervous system.
    Pochet R; Timmermans JP
    Anat Rec (Hoboken); 2009 Dec; 292(12):1847-8. PubMed ID: 19943338
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of α-synuclein in neurotransmission and synaptic plasticity.
    Cheng F; Vivacqua G; Yu S
    J Chem Neuroanat; 2011 Dec; 42(4):242-8. PubMed ID: 21167933
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tuning and fine-tuning of synapses with adenosine.
    Sebastião AM; Ribeiro JA
    Curr Neuropharmacol; 2009 Sep; 7(3):180-94. PubMed ID: 20190960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases].
    Chen J; Wang ZF
    Sheng Li Xue Bao; 2010 Aug; 62(4):295-308. PubMed ID: 20717630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rab-mediated endocytosis: linking neurodegeneration, neuroprotection, and synaptic plasticity?
    Baskys A; Bayazitov I; Zhu E; Fang L; Wang R
    Ann N Y Acad Sci; 2007 Dec; 1122():313-29. PubMed ID: 18077583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulation and metamodulation of synapses by adenosine.
    Ribeiro JA; Sebastião AM
    Acta Physiol (Oxf); 2010 Jun; 199(2):161-9. PubMed ID: 20345418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.